Presentation - Novartis

download Presentation - Novartis

of 13

  • date post

    12-Mar-2016
  • Category

    Documents

  • view

    227
  • download

    1

Embed Size (px)

description

Dr. Stephan Mumenthaler

Transcript of Presentation - Novartis

  • Dr. Stephan Mumenthaler Head Economic and Swiss Public Affairs Istanbul, November 22, 2012

    Innovation through Corporate R&D

  • Leading market position

    One of 35 largest companies by market capitalization

    Among most respected companies globally

    Novartis is a world-leading healthcare company

    2011 CHF billion

    Net sales: 51.8

    Net income: 8.2

    R&D investment: 8.5

    Key figures Canada/ Latin America

    US

    Europe Asia/Africa/ Australasia

    Sales by region 2011

    1 CHF = USD 1.13

    2 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012

  • We believe our portfolio best meets the varied and often complex needs of patients and societies Environment Patient needs Novartis portfolio

    Pharmaceuticals

    Vaccines and Diagnostics

    Sandoz (Generics)

    Full range of healthcare options

    Innovative medicines Prevention Affordable options Self-care

    Alcon (Eye care)

    Consumer Health (OTC and Animal Health)

    3 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012

  • Novartis

    Pfizer/Wyeth

    Merck/SGP

    Roche/Genentech

    BMS

    AstraZeneca

    J&J**

    Sanofi-Aventis

    Eli Lilly

    Bayer

    GSK

    US FDA EU EMA Japan PMDA China SFDA

    15

    11

    10

    13

    6

    3

    5

    4

    5 5

    2

    8

    3

    6

    5

    6

    4

    3

    2

    1

    3

    1

    Notes: Does not include vaccines; Novartis includes Alcon and co-developed or co-marketed products from Ciba Vision, QLT, Idenix, Genentech; Pfizer includes products of Pharmacia + Wyeth; Merck includes products of Schering Plough + Organon; Roche includes products of Genentech and Chugai (JP); J&J includes products of Janssen +Centocor+ RWJohnson EU approvals for all companies are inclusive of fixed-dose combinations and confirmed EC decisions Source: FDA, EMA, PMDA, SFDA/CDE databases (as of 31 Jan 2012)

    New chemical/molecular entity (NCE/NME) approvals for selected companies 2007 2011

    By leveraging our R&D capabilities, we are leading the industry in productivity

    4

    6

    3

    1

    3

    3

    4

    8

    3

    2

    13

    3

    1

    1

    3

    2

    8

    10

    9

    10

    12

    17

    4 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012

  • Novartis Pharma and Corporate Research and Development 2012: worldwide community 2012

    Emeryville (USA): NIBR

    La Jolla (USA): GNF, Genomics Institute

    East Hanover (USA): NIBR & Pharma Development

    Alcon Forth Worth (USA): Ophtalmology

    Cambridge (USA): NIBR, Pharma Development,

    Vaccines Research

    Horsham (UK): NIBR & Pharma

    Development Basel (CH): NIBR, Pharma Development & Friedrich Miescher Institute for

    Biomedical Research (FMI)

    Siena (IT): Vaccines

    NITD Singapore (SG): Tropical Diseases

    Shanghai & Changshu (CN): NIBR & Pharma

    Development

    Hyderabad (IN): Pharma

    Development

    Tokyo (JP): Pharma

    Development

    5 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012

  • The most important research center of Novartis is Switzerland

    Novartis is continually investing in R&D in Switzerland In 2011 the R&D investment amounted to 3.3 billion francs The research programs are supported by cooperative ventures, for

    example with the prestigious Paul Scherrer Institute

    Basel is not only the global headquarters of Novartis, but also its largest research center Around 13 550 associates

    are employed in Switzerland, over 2 800 of them in research

    Basels Friedrich Miescher Institute is also part of the global research network of Novartis

    6 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012

  • Innovations require attractive framework conditions

    protection of intellectual property attractive tax system political und economical stability

    enterprise-friendly framework conditions

    uncomplicated raise of capital beneficial interest rates promote risk capital for spin-offs

    creation of investment incentives

    price differentiation recoveries market access

    protection and promotion of innovations

    focusing on the needs of leading scientists (e.g. international schools) attracting leading scientists

    allocate educational resources to develop specific areas of competence

    foster natural sciences foster educational

    competence

    7 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012

  • Switzerland is one of the most innovative and competitive economies

    Factors considered: Institutions, infrastructure, macro-economic stability, health and elementary school education, university education and training, efficiency of capital goods markets, jobs market efficiency, development of financial markets, technological developments, market size, developent of companies and innovation

    Rank 1 Rank 2 Rank 3 Rank 4 Rank 5

    Source: EVD (2102)

    8 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012

  • Switzerlands strengths

    Legal Security 1848 Original form of Swiss constitution

    Integration 23% of the population are foreigners

    Education 61% of school pupils are in a dual system

    Discipline 98% of trains run on time

    Industry 83% of 15 to 64- year-olds are in work

    Endurance 34 years Rail 2000

    9 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012

  • But there are also weaknesses: Switzerland is a very high wage country

    Source: BfS (2012)

    Labot costs per hour,

    in euros

    40.0 30.0 39.9 20.0 29.9 10.0 19.9 < 10.0 No data

    10 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012

  • Most OECD countries promote R&D with tax incentives not Switzerland

    Direct government funding of business R&D and tax incentives for R&D, 2009, as a percentage of GDP

    0.000.050.100.150.200.250.300.350.40

    Sw

    itzer

    land

    Finl

    and

    Ger

    man

    y

    Sw

    eden

    Sou

    th A

    frica

    Spa

    in

    Bra

    zil

    Turk

    ey

    Nor

    way

    Uni

    ted

    Stat

    es

    Japa

    n

    Uni

    ted

    King

    dom

    Aus

    tralia

    Aus

    tria

    Hun

    gary

    Por

    tuga

    l

    Net

    herla

    nds

    Slo

    veni

    a

    Irela

    nd

    Bel

    gium

    Can

    ada

    Fran

    ce

    Direct government funding of BERD Indirect government support through R&D tax incentivesSource: OECD SCIENCE, TECHNOLOGY AND INDUSTRY SCOREBOARD 2011

    11 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012

  • Improving the investment environment and encouraging foreign investment

    Increasing production output for export: Increasing exports by an average of 11.2 percent annually at current prices, for USD 185.1 billion by 2014 and USD 500 billion by 2023

    Reducing the current account deficit from 9.4% to 7% as a percentage of GDP by 2014

    Increasing total R&D Expenditure as a percentage of GNP to 2% by 2013, and to 3% by 2023

    Supporting R&D and Innovation: Completing regulatory preparations, promoting establishment of laboratories, and facilitating systems of conformity assessment and market oversight to improve product quality and ensure safety of marketed products, to develop a capacity for producing high added-value products.

    TURKEY 3- Year Medium-Term Program and Vision 2023

    12 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012

  • Fostering Innovation Policy Recommendations Attractive framework conditions for

    leading class scientific companies which aspire to invest (e.g. IP, tax system)

    Provide investment incentives comparable to other countries (e.g. Singapore)

    Protect and foster innovation (e.g. differentiated pricing, reimbursement, market access)

    Increase attractiveness of location for leading researchers (e.g. international schools, infrastructure)

    Build education portfolio with focus on competence fields (foster natural sciences)

    13 | Innovation through Corporate R&D | Dr. Stephan Mumenthaler | November 22, 2012

    Innovation through Corporate R&DNovartis is a world-leading healthcare companyWe believe our portfolio best meets the varied and often complex needs of patients and societiesBy leveraging our R&D capabilities, we are leading the industry in productivityNovartis Pharma and Corporate Research and Development 2012: worldwide community 2012The most important research center of Novartis is SwitzerlandInnovations require attractive framework conditionsSwitzerland is one of the most innovative and competitive economiesSwitzerlands strengthsBut there are also weaknesses: Switzerland is a very high wage countryMost OECD countries promote R&D with tax incentives not SwitzerlandTURKEY3- Year Medium-Term Program and Vision 2023Fostering Innovat